Oragenics INC (OGEN) — 8-K Filings

All 8-K filings from Oragenics INC. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

Oragenics Inc. Files 8-K with Financials and Exhibits — Apr 13, 2026 Risk: low
On April 13, 2026, Oragenics Inc. filed an 8-K report detailing other events. The filing includes financial statements and exhibits, with the primary document b
Oragenics Reports Director/Officer Changes & Financials — Dec 15, 2025 Risk: medium
Oragenics, Inc. filed an 8-K on December 15, 2025, reporting events as of December 11, 2025. The filing covers the departure of directors or certain officers, t
8-K Filing — Nov 12, 2025
Oragenics Files 8-K on Agreement and Listing Concerns — Oct 21, 2025 Risk: high
Oragenics, Inc. filed an 8-K on October 21, 2025, reporting a material definitive agreement and a notice of delisting or failure to meet listing standards. The
Oragenics Files 8-K: Director/Officer Changes & Financials — Sep 2, 2025 Risk: medium
Oragenics, Inc. filed an 8-K on September 2, 2025, reporting events as of September 1, 2025. The filing indicates changes related to the departure of directors
Oragenics Inc. Files 8-K Report — Aug 11, 2025 Risk: low
On August 11, 2025, Oragenics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
Oragenics Files 8-K with Material Agreements and Bylaw Changes — Jul 2, 2025 Risk: medium
On June 30, 2025, Oragenics, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, modifications t
Oragenics Files 8-K: Security Holder Rights & Bylaws Amended — May 28, 2025 Risk: medium
Oragenics, Inc. filed an 8-K on May 28, 2025, reporting material modifications to security holder rights and amendments to its articles of incorporation or byla
8-K Filing — May 20, 2025
Oragenics Files 8-K: Material Agreements, Officer Changes, Shareholder Votes — May 2, 2025 Risk: medium
On May 2, 2025, Oragenics, Inc. filed an 8-K report detailing several key events. These include the entry into a material definitive agreement, changes in direc
Oragenics Inc. Files 8-K Report — Apr 9, 2025 Risk: low
On April 9, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material e
Oragenics Inc. Files 8-K Report — Mar 27, 2025 Risk: low
On March 27, 2025, Oragenics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosur
Oragenics Inc. Files 8-K Report — Mar 6, 2025 Risk: low
On March 6, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
Oragenics Files 8-K on Shareholder Nominations & Financials — Feb 18, 2025 Risk: low
Oragenics, Inc. filed an 8-K on February 18, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11 and including financial statements
Oragenics Files 8-K Report — Feb 5, 2025 Risk: low
On February 5, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updat
Oragenics Files 8-K with Financials and Exhibits — Jan 21, 2025 Risk: low
On January 21, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, indicating routine
Oragenics Reports Governance Changes and New Agreements — Jan 17, 2025 Risk: medium
On January 15, 2025, Oragenics, Inc. reported a material definitive agreement, the departure of directors or certain officers, and the election of directors. Th
Oragenics Announces Director Changes and New CMO — Dec 16, 2024 Risk: medium
Oragenics, Inc. announced on December 11, 2024, several key events including the departure of director Dr. David G. Murdock, the election of new directors Dr. M
Oragenics Terminates Material Definitive Agreement — Nov 29, 2024 Risk: medium
Oragenics, Inc. filed an 8-K on November 29, 2024, reporting the termination of a material definitive agreement as of November 26, 2024. The filing also include
Oragenics Inc. Files 8-K Report — Oct 18, 2024 Risk: low
On October 18, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and
Oragenics Inc. Files 8-K Report — Oct 16, 2024 Risk: low
On October 15, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and E
Oragenics Inc. Files 8-K for Material Definitive Agreement — Oct 15, 2024 Risk: medium
On October 11, 2024, Oragenics Inc. entered into a material definitive agreement. The company, incorporated in Florida with its principal executive offices in S
Oragenics Inc. Files 8-K Report — Oct 9, 2024 Risk: low
On October 9, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a routine dis
Oragenics Announces Board and Executive Changes — Sep 20, 2024 Risk: medium
Oragenics, Inc. announced on September 19, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of
Oragenics Files 8-K: Material Agreement, Other Events — Sep 5, 2024 Risk: medium
On September 4, 2024, Oragenics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial stateme
Oragenics Files 8-K with Corporate Updates — Aug 21, 2024 Risk: low
Oragenics, Inc. filed an 8-K on August 21, 2024, reporting other events and financial statements. The filing details the company's corporate structure, includin
Oragenics Faces Delisting Concerns — Aug 16, 2024 Risk: high
Oragenics, Inc. filed an 8-K on August 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicate
Oragenics Inc. Files 8-K with Financial Statements — Aug 14, 2024 Risk: low
On August 14, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclos
Oragenics Files 8-K Report — Aug 12, 2024 Risk: low
On August 12, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific finan
Oragenics Inc. Files 8-K Report — Aug 8, 2024 Risk: low
On August 8, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
Oragenics Inc. Files 8-K Report — Jul 22, 2024 Risk: low
On July 22, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
Oragenics Files 8-K Report — Jul 10, 2024 Risk: low
On July 10, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
Oragenics, Inc. Files 8-K: Material Definitive Agreement — Jun 26, 2024 Risk: medium
On June 25, 2024, Oragenics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibi
Oragenics Inc. Faces Delisting Notice — Jun 20, 2024 Risk: high
Oragenics, Inc. filed an 8-K on June 18, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is located at 1990 Ma
Oragenics Files 8-K on Shareholder Nominations — May 23, 2024 Risk: medium
On May 23, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns shareholder nominations pursuant to Exchange Act Rule 14a-11, indicating pot
Oragenics Files 8-K Report — May 22, 2024 Risk: low
On May 22, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure
Oragenics Inc. Files 8-K Report — May 17, 2024 Risk: low
On May 17, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statements and exhibi
Oragenics Inc. Files 8-K Report — May 16, 2024 Risk: low
On May 16, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a
Oragenics Files 8-K: Other Events & Financials — May 7, 2024 Risk: low
Oragenics, Inc. filed an 8-K on May 7, 2024, reporting other events and financial statements/exhibits. The company, incorporated in Florida with its principal e
Oragenics Faces Delisting Concerns — Apr 22, 2024 Risk: high
On April 18, 2024, Oragenics, Inc. filed an 8-K report detailing its notice of delisting or failure to satisfy continued listing rules. The company is also addr
Oragenics Files 8-K on Shareholder Nominations — Apr 16, 2024 Risk: medium
On April 15, 2024, Oragenics, Inc. filed an 8-K report to disclose information regarding shareholder nominations. The filing pertains to Rule 14a-11 of the Exch
Oragenics Files 8-K Report — Mar 18, 2024 Risk: low
On March 18, 2024, Oragenics, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific fi
Oragenics, Inc. Files 8-K: Material Agreement & Equity Sales — Mar 1, 2024 Risk: medium
On February 27, 2024, Oragenics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and pro
Oragenics Files 8-K on Feb 27, 2024 — Feb 28, 2024 Risk: low
Oragenics, Inc. filed an 8-K on February 27, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates a current report p
Oragenics Reports Executive Changes & Compensation on Feb 12 — Feb 12, 2024 Risk: medium
Oragenics, Inc. filed an 8-K on February 12, 2024, to report the departure of directors or certain officers, election of directors, appointment of certain offic
Oragenics Files 8-K on Feb 7, Confirms NYSE American Listing — Feb 7, 2024
Oragenics, Inc. filed an 8-K on February 7, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the company's C
Oragenics Files 8-K on Feb 5, Confirms NYSE American Listing — Feb 5, 2024
Oragenics, Inc. filed an 8-K on February 5, 2024, indicating an 'Other Event' and 'Financial Statements and Exhibits.' This filing primarily serves to update th
Oragenics (OGEN) Terminates Material Definitive Agreement — Jan 23, 2024
Oragenics, Inc. (OGEN) filed an 8-K on January 23, 2024, to report the termination of a material definitive agreement. This filing indicates a significant chang
Oragenics Files 8-K, Confirms NYSE American Listing — Jan 16, 2024
Oragenics, Inc. filed an 8-K on January 16, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing primarily serves to update adm
Oragenics Files 8-K on Jan 2, 2024; Confirms NYSE American Listing — Jan 2, 2024
Oragenics, Inc. filed an 8-K on January 2, 2024, to report an "Other Event" and provide information on "Financial Statements and Exhibits." This filing primaril

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX